ADMA BIOLOGICS DL-,0001

A federal securities lawsuit filed in the U.S. District Court for the District of New Jersey alleges ADMA Biologics inflated revenues for its flagship product through channel stuffing and hid a distribution relationship tied to an entity allegedly controlled by a senior executive. The complaint claims ADMA and certain senior executives made materially false statements about revenue growth, internal controls and related-party transactions, following a March short-seller report by Culper Research. ADMA shares plunged in late March after the short report, and recent analyst coverage resumed with a bullish outlook despite the legal scrutiny. » Mais em finance.yahoo.com

FDA approved an expanded indication for ADMA Biologics' ASCENIV to treat pediatric patients aged two years and older, down from the previous 12‑year threshold, following a post‑marketing pediatric assessment. The company will prioritize ASCENIV for earlier pediatric care, a milestone CEO Adam Grossman said enables treatment of younger immune‑compromised patients. ASCENIV is a plasma‑derived intravenous immune globulin produced using ADMA’s donor screening and pooling methods. » Mais em finance.yahoo.com

ADMA Biologics reported Q1 2026 EPS of $0.19 (forecast $0.20) and revenue of $114.5 million, well below the expected $142.74 million. Strong growth in ASCENIV (+28% year-over-year) was offset by a decline in BIVIGAM (-54%); gross margin was 71% and adjusted EBITDA rose 24%. The stock reacted only mildly negative and recovered in after-hours trading; management emphasizes expanding sales and capacity but sees ongoing competition and pricing pressure as the main risks. » Mais em de.investing.com